LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.  

LENZ Therapeutics

Specialty Sales Representative, Eye Care - San Diego, CA

Medical Science Liaison (MSL)

National Director, Sales Training

Staff Accountant (AP/AR)

IT Specialist

VP/SVP, Human Resources

Specialty Sales Representative, Eye Care - Honolulu, HI

[PRESS RELEASE - LENZ Therapeutics x Laboratoires Théa]
We’re pleased to announce a licensing agreement between LENZ Therapeutics and Laboratoires Théa to bring LNZ100 to the Canadian market. LNZ is a preservative-free ophthalmic solution formulated with aceclidine, which is under evaluation by FDA for the treatment of presbyopia in adult patients.
 
As part of this agreement, Théa will initiate the regulatory process with Health Canada immediately. Our shared goal: to provide eye care professionals with a new treatment option to support patients managing presbyopia—as a complement to glasses or contact lenses.
 
“Canada is an important part of Théa’s international development, and we have been active in the country for several years. Our local team plays an essential role in supporting both patients and eye care professionals. This partnership with LENZ will expand our portfolio with a promising therapy targeting a prevalent condition that affects millions of adults. We see strong potential for LNZ100 in Canada and look forward to initiating the registration process and making the treatment available to Canadian healthcare providers and their patients.” - Jean-Frédéric Chibret, President, Laboratoires Théa.

👉 Read the full press release here: https://bit.ly/407qe8F 
#Thea #LENZTherapeutics #Presbyopia #OphthalmologyInnovation #LNZ100 #NearVision


Chris Lievens, OD MS PhD, is motivated by an innovative presbyopia treatment that ensures better results for him and his patients. 
 
"As both a practitioner and a presbyope, I'm anticipating the transformative impact a new solution could have on my own life and the lives of my patients."
 
www.EyeAmSelective.com
#presbyopia 

LENZ Therapeutics, Inc. SEC 10-K Report - TradingView

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress - Business Wire

Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Therapeutics - PR Newswire

Join LENZ Therapeutics at American Society of Cataract and Refractive Surgery (ASCRS) this week.

Stop by booth #1359 to learn more about the future of presbyopia solutions.

 A gene editing biotech's struggles end with reverse merger 

Join LENZ Therapeutics at American Optometric Association this week.

Stop by booth #1207 to learn more about the future of presbyopia solutions.

Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

 LENZ Therapeutics to Present at Upcoming Investor Conferences 

LENZ Therapeutics concludes merger with Graphite Bio - Pharmaceutical Technology

 Lenz Therapeutics' Growth at Risk Amid IP Licensing Battles in Competitive Pharma Landscape - TipRanks.com 

Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100 - TipRanks

 Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c) 

Lenz presbyopia drop meets endpoints in near vision improvement in phase 3 trials - Healio

 LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital 

LENZ Therapeutics' LNZ100 Hits FDA Milestone, Reports 74% Success in Phase 3 Trial - StockTitan

LENZ Therapeutics welcomes Apple Decena as our new Senior Accountant. Apple brings a strong background in accounting and has over 8 years of experience in Accounts Receivable and Accounts Payable roles. 

Join us in welcoming Apple to the team!

LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com

 LENZ Therapeutics reports positive Phase 3 results for LNZ100 By Investing.com 

LENZ Therapeutics and Graphite Bio enter merger deal - Pharmaceutical Technology

LENZ Therapeutics welcomes Marianna Rabinovich as our new Manager of Payroll and Equity Administration. Marianna joins us with nearly 20 years of experience in the HR and Payroll field, with the last 6 years exclusively in the biotech industry, including Poseida Therapeutics, Zentalis Inc. and Bionano. 

Join us in welcoming Marianna to the team!

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

 TD Cowen Upgrades LENZ Therapeutics Inc (LENZ) to Buy 

LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - MarketWatch

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision By Investing.com - Investing.com South Africa

Presbyopia Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight - The Globe and Mail

Lenz Therapeutics: Upcoming PDUFA, Strong Data, Some Risks (NASDAQ:LENZ) - Seeking Alpha

LENZ Therapeutics announces positive results from Phase 3 CLARITY trials - Optometry Times

LENZ Therapeutics welcomes Kashif Qadeer, O.D. as a Medical Science Liaison in Southern California.

Kashif earned his Doctor of Optometry degree from the Southern California College of Optometry in 2007, following early research experience in ocular medications. He completed a residency in Ocular Disease at the VA Eye Clinic in Las Vegas, then worked in a large ophthalmology practice focusing on LASIK co-management, contact lenses, and clinical research. He later ran a successful two-location private practice in Orange County for over 13 years. Most recently, he returned to the industry side, contributing to clinical research with a major pharmaceutical company.

Join us in welcoming Kashif to the team!

Graphite Bio Approves Merger, Name Change, and Stock Split - TipRanks

 We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth 

LENZ Therapeutics: Time For A Pause (NASDAQ:LENZ) - Seeking Alpha

 LENZ Therapeutics to Host Commercial Day on April 15, 2025 

Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan

LENZ Therapeutics welcomes Mina Ghazizadeh as a Human Resources Generalist. 

Mina attended the University of San Diego, where she played on the women’s soccer team, before earning her graduate degree in Industrial/Organizational Psychology. Most recently, she worked as the People & Culture Specialist with the Portland Trail Blazers. 

Join us in welcoming Mina to the team!

LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq

LENZ Therapeutics welcomes Mansi Parikh, OD as a Medical Science Liaison in the Mid-South. 

Mansi earned her Doctor of Optometry from the New England College of Optometry and spent six years owning and operating multiple subleased clinics across the greater Atlanta area. Her interest in innovation led her to contribute to human factors research, where she applied clinical insights to improve the safety and usability of wearable devices. Most recently, she served as a Clinical Research Optometrist where she served as an investigator for contact lens clinical trials. 

 
Join us in welcoming Mansi to the team!

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - Stock Titan

 LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada 


                Earnings Release
                HTML
            

Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com

rss_feedRSS News Feed

LENZ Therapeutics welcomes Beth Samenuk as National Account Director. Beth joins us with over 15 years of experience leading high-performing teams across the eyecare space. She brings diverse expertise to LENZ including strategic partnerships, market expansion, and innovative healthcare delivery models. Her track record of successfully launching groundbreaking products and services, coupled with her entrepreneurial approach to market development, makes her a key asset to LENZ.

Beth's previous leadership experience pioneering telehealth platforms, improving patient access, and developing novel healthcare delivery models further underscores her extensive expertise, which will be critical in developing and executing our market strategy.

Join us in welcoming Beth to the team!

 Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress 

We are hiring! LENZ Therapeutics is searching for a Sr. Regulatory Operations Specialist. 

This position will be responsible for formatting and publishing regulatory submissions, supporting the implementation and maintenance of our Regulatory Information Management and publishing systems, and ensuring compliance with regulatory submissions requirements throughout the product lifecycle. 

Read the full description and click the link to apply: https://lnkd.in/gWSAjYU3 

LENZ reports positive results from presbyopia treatment trial - Clinical Trials Arena

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials - Business Wire

 LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 

LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers

We are hiring! LENZ Therapeutics is searching for a Quality Specialist (Product Complaint).

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products. Position focus is supporting Product Complaint process for commercial product.

Read the full job description and click link below to apply: https://lnkd.in/gcrP2apH 

Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - Stock Titan

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat

LENZ Therapeutics Hosts Commercial Day for LNZ100 - TipRanks

Mark Schaeffer, OD, FAAO believes presbyopia solutions are active and continuously changing. 
 
"The presbyopia market is dynamic. It reflects our patients’ evolving visual needs and their desire for a solution that provides clear vision on their own terms. Vision is dynamic, too—so shouldn’t we consider a solution that mirrors that?"
 
 www.EyeAmSelective.com
 #presbyopia

 LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights 

LENZ Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

 LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference 

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study - ETHealthWorld

View All News

Latham Watkins Advises on US53 5 Private Placement Financing in Connection With LENZ Therapeutics - Latham & Watkins LLP

LENZ Therapeutics welcomes Tori Renfro as Quality Specialist. 

Tori brings several years of experience in quality control and manufacturing within regulated environments. Most recently, she worked as a Quality Control Scientist, focusing on compliance, cross-functional support, and continuous improvement. Tori will be responsible for managing our product complaint process and assisting in batch release.

Join us in welcoming Tori to the team!

We are hiring! LENZ Therapeutics is searching for a Supply Chain Logistics Coordinator. 

This position will support the commercialization of LNZ100 at LENZ. This critical role will focus on coordinating international and domestic shipments and ensuring timely delivery of materials and finished goods through our external manufacturing and warehousing partners. 

Read the full description and click the link to apply: https://lnkd.in/g3pkQfTv 


LENZ Therapeutics, Inc.

 Geopolitics, rates drag on private equity deals; Israel's high PE ... 

 Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement 

LENZ Therapeutics welcomes Fikret Kajoshaj, O.D. as a Medical Science Liaison in the Southeast. 

Fikret graduated from Nova Southeastern University in Fort Lauderdale, Florida where he obtained his Doctor of Optometry degree in 2013. Fikret furthered his training and completed an ocular disease residency at VA Hudson Valley Health Care System in Westchester County, NY. Fikret practiced and gained extensive and valuable clinical experience working at several different ophthalmology clinics and was a Key Opinion Leader for BioTissue in 2016. 
 
Join us in welcoming Fikret to the team!

 LENZ Therapeutics Reports Third Quarter 2024 Financial Results 

A gene editing biotech’s struggles end with reverse merger - BioPharma Dive

 LENZ Therapeutics Merges With Graphite Bio 

Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - Stock Titan

 Graphite Bio hands Nasdaq spot to presbyopia biotech Lenz Therapeutics as PhIII readouts loom 

LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com

San Diego’s Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses - San Diego Union-Tribune

We are hiring! LENZ Therapeutics is searching for a Sr. Quality Specialist.

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products.

Other responsibilities for this role include date review and verification, support administration of electronic QMS and Regulatory software(s), product complaint handling and management review program. 

If you are ready to join our team, click link below to apply: https://lnkd.in/gmEr7VXj

Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio - Wilson Sonsini

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - MSN

Lenz Therapeutics Raises $47M in Series A Financing - FinSMEs

LENZ Therapeutics gets fresh set of eyes with $47M funding to bring eyedrop to market - Fierce Biotech

Mitch Ibach, OD FAAO is curious about discovering the potential advancements in presbyopia solutions. 
 
"I'm curious to see how presbyopes adopt a new solution and the near-vision improvement they can achieve. Finding the right treatment for each patient is crucial. Curiosity drives me to seek better options for clearer vision, and I'm eager to explore how future solutions can complement existing treatments."
 
www.EyeAmSelective.com
#presbyopia 

Investors & Media

 Lenz Therapeutics' eye drop helps improve vision in late-stage study 

Strong Buy Recommendation for LENZ Therapeutics: LNZ100 Poised to Disrupt Presbyopia Market with Best-in-Class Efficacy and Safety - TipRanks

LENZ Therapeutics to Host Webcast on First Quarter 2025 Financial Results and Corporate Developments - Nasdaq

Behind the Bell: LENZ Therapeutics - Nasdaq

LENZ Therapeutics Finds $83.5M In Series B - socalTech.com

See results

Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz - Fierce Biotech

 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and ... 

LENZ Therapeutics welcomes Joseph B. as Regional Sales Director, East Coast. Joseph comes to LENZ with over 10 years of experience rebuilding and leading high performing teams in multiple specialties. Joseph has extensive experience in eye care from his time at Aerie and Alcon. Joseph also brings a diverse business background to LENZ, including CPG sales, Trade Marketing, Retail Sales Management, and multiple Leadership Certifications. His vast experience in Sales Leadership has helped Joe develop an award winning and successful track record over his career including several President Club Awards. These skills will make Joe a key player as we drive towards commercial readiness.

Join us in welcoming Joe to the team!

 Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics 

GRAPHITE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

We are hiring! LENZ Therapeutics is searching for a Director, Regulatory CMC. 

This role will support the development and successful performance of the CMC regulatory strategy for LENZ Therapeutics. This position is based in San Diego, CA and reports to the VP, Regulatory and Clinical Operations.

Read the full description and click the link to apply: https://lnkd.in/g9UzGBEB 

 Lenz Therapeutics management to meet with Piper Sandler 

LENZ Therapeutics inks exclusive commercialization agreement with Lotus Pharmaceutical - MSN

Graphite Erased: LENZ to Merge with Gene Editing Therapy Developer - Genetic Engineering & Biotechnology News

 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights 

LENZ Therapeutics gets fresh set of eyes with $47M ...

LENZ Therapeutics

Business:

About: